Articles related to PSYCHEDELICS

Note that many questions remain after this trial returned results that are not unequivocally positive. The prespecified primary outcome was negative, which limits claims of efficacy and argues against overinterpreting the study as confirmatory evidence for psilocybin in treatment-resistant depression.

“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways

A new network meta-analysis reveals that high-dose psilocybin may be as effective as escitalopram for treating depressive symptoms, with a standardized mean difference of 0.31 compared to placebo in antidepressant trials.

The use of psychedelics in treating substance use disorder (SUD) is showing promise. A 2012 meta-analysis suggests a favorable probability of reduced alcohol use upon administration of LSD in a controlled context.

A Phase 2B study found that a 25mg dose of psilocybin, combined with psychotherapy, produced a significant drop in patients’ scores on the Montgomery Asberg Depression Rating Scale (MADRS) after 12 weeks. This finding underscores the potential of psilocybin-assisted therapy as a promising treatment for depression.

Discover how MDMA-assisted therapy is setting new benchmarks in PTSD treatment, offering clinically meaningful improvements and a strong safety profile.